These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 1548679

  • 1. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
    Youssefyeh RD, Campbell HF, Airey JE, Klein S, Schnapper M, Powers M, Woodward R, Rodriguez W, Golec S, Studt W.
    J Med Chem; 1992 Mar 06; 35(5):903-11. PubMed ID: 1548679
    [Abstract] [Full Text] [Related]

  • 2. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
    Youssefyeh RD, Campbell HF, Klein S, Airey JE, Darkes P, Powers M, Schnapper M, Neuenschwander K, Fitzpatrick LR, Pendley CE.
    J Med Chem; 1992 Mar 06; 35(5):895-903. PubMed ID: 1312602
    [Abstract] [Full Text] [Related]

  • 3. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
    Fitzpatrick LR, Lambert RM, Pendley CE, Martin GE, Bostwick JS, Gessner GW, Airey JE, Youssefyeh RD, Pendleton RG, Decktor DL.
    J Pharmacol Exp Ther; 1990 Aug 06; 254(2):450-5. PubMed ID: 2166791
    [Abstract] [Full Text] [Related]

  • 4. 5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.
    Hayashi H, Miwa Y, Ichikawa S, Yoda N, Miki I, Ishii A, Kono M, Yasuzawa T, Suzuki F.
    J Med Chem; 1993 Mar 05; 36(5):617-26. PubMed ID: 8496941
    [Abstract] [Full Text] [Related]

  • 5. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
    Fernández AG, Puig J, Beleta J, Doménech T, Bou J, Berga P, Gristwood RW, Roberts DJ.
    Eur J Pharmacol; 1992 Nov 10; 222(2-3):257-64. PubMed ID: 1451737
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML, Bloomquist W, Gidda JS, Lacefield W.
    J Pharmacol Exp Ther; 1989 Jan 10; 248(1):197-201. PubMed ID: 2521513
    [Abstract] [Full Text] [Related]

  • 7. RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo.
    Eglen RM, Lee CH, Smith WL, Johnson LG, Whiting RL, Hegde SS.
    J Pharmacol Exp Ther; 1993 Aug 10; 266(2):535-43. PubMed ID: 8355189
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. 5-HT3 receptor agonism may be responsible for the emetic effects of zacopride in the ferret.
    Middlefell VC, Price TL.
    Br J Pharmacol; 1991 May 10; 103(1):1011-2. PubMed ID: 1831684
    [Abstract] [Full Text] [Related]

  • 10. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
    Gidda JS, Evans DC, Cohen ML, Wong DT, Robertson DW, Parli CJ.
    J Pharmacol Exp Ther; 1995 May 10; 273(2):695-701. PubMed ID: 7752072
    [Abstract] [Full Text] [Related]

  • 11. Zacopride, a potent 5-HT3 antagonist.
    Smith WW, Sancilio LF, Owera-Atepo JB, Naylor RJ, Lambert L.
    J Pharm Pharmacol; 1988 Apr 10; 40(4):301-2. PubMed ID: 2900319
    [Abstract] [Full Text] [Related]

  • 12. Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets.
    Yamakuni H, Nakayama H, Matsui S, Imazumi K, Matsuo M, Mutoh S.
    J Pharmacol Sci; 2006 May 10; 101(1):99-102. PubMed ID: 16651699
    [Abstract] [Full Text] [Related]

  • 13. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T, Yoshida N, Oka M.
    Br J Pharmacol; 2001 May 10; 133(2):253-60. PubMed ID: 11350861
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties.
    Blackburn TP, Baxter GS, Kennett GA, King FD, Piper DC, Sanger GJ, Thomas DR, Upton N, Wood MD.
    Psychopharmacology (Berl); 1993 May 10; 110(3):257-64. PubMed ID: 7831418
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antagonistic activity of Y-25130 on 5-HT3 receptors.
    Sato N, Sakamori M, Haga K, Takehara S, Setoguchi M.
    Jpn J Pharmacol; 1992 Aug 10; 59(4):443-8. PubMed ID: 1331590
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
    Hirokawa Y, Harada H, Yoshikawa T, Yoshida N, Kato S.
    Chem Pharm Bull (Tokyo); 2002 Jul 10; 50(7):941-59. PubMed ID: 12130853
    [Abstract] [Full Text] [Related]

  • 20. The antiemetic profile of zacopride.
    Smith WL, Alphin RS, Jackson CB, Sancilio LF.
    J Pharm Pharmacol; 1989 Feb 10; 41(2):101-5. PubMed ID: 2568416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.